Skip to main content
Clinical Trials/NCT05971368
NCT05971368
Recruiting
Not Applicable

A Comparative Study Between Ultrasound Guided Thoracic Paravertebral Block VS Ultrasound Guided Serrartus Anterior Muscle Block in Video-assisted Thoracoscopic Surgeries.

Ain Shams University1 site in 1 country80 target enrollmentJune 4, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Post Operative Pain, Acute
Sponsor
Ain Shams University
Enrollment
80
Locations
1
Primary Endpoint
visual analog scale (VAS)
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

A comparative study between ultrasound guided thoracic paravertebral block VS ultrasound guided serrartus anterior muscle block in video-assisted thoracoscopic surgeries as regard their effectiveness in post-operative analgesia

Detailed Description

The use of loco-regional analgesia is recommended to control postoperative pain after VATS as it allows opioid sparing and facilitates early postoperative rehabilitation. Different loco-regional analgesic techniques could be used to control pain after thoracic surgery such as a paravertebral block, an intercostal block and serratus plane block. In this study, Thoracic paravertebral nerve block will be compared to Serratus anterior nerve block, both will be done Ultrasound guided (USG) using bupivacaine (0.25%) for postoperative analgesia.

Registry
clinicaltrials.gov
Start Date
June 4, 2022
End Date
February 10, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients American Society of Anesthesiologists physical status (ASA) I to II
  • Both sexes.
  • Aged ≥ 20 to ≤ 65years.
  • Scheduled for VATS under general anesthesia.

Exclusion Criteria

  • Patient's refusal.
  • Patients American Society of Anesthesiologists physical status (ASA) III to IV
  • Patients with major spine deformities.
  • Disruption of the local anatomy, secondary, for instance, to the presence of chest drains or surgical emphysema, resulting in difficulty in ultrasound interpretation and distortion of tissue planes.
  • Patients with bleeding disorders and coagulopathy.
  • Infection at the injection site.
  • Known allergy to local anesthetics.
  • Patients with pre-existing myopathy or neuropathy.
  • Ipsilateral diaphragmatic paresis.
  • Tumors in the paravertebral space at the level of injection.

Outcomes

Primary Outcomes

visual analog scale (VAS)

Time Frame: the first 24 hours postoperatively

Postoperative pain will be assessed at time of evaluation or at any time the patient is complaining of pain by using visual analog scale (VAS) and VAS more than 4 will be managed by injection of nalbuphine 5mg intravenously as a first rescue analgesia to reduce VAS score ≤ 3

total amount of opioid consumption in the two groups according to change in VAS score

Time Frame: the first 24 hours postoperatively

Postoperative pain will be assessed at time of evaluation or at any time the patient is complaining of pain by using visual analog scale (VAS) and VAS more than 3 will be managed by injection of nalbuphine 0.05mg / kg intravenously as a first rescue analgesia to reduce VAS score ≤ 3 and another titrating dose (2-3 mg nalbuphine) will be considered if the patient is still complaining in order to reach VAS score ≤ 3 (with maximum dose of 10 mg nalbuphine at a time)

Secondary Outcomes

  • onset of ambulation(first 24 hours postoperatively)
  • The onset of 1st analgesic request(The first 24 hours postoperatively)
  • mean arterial blood pressure of the patients(first 24 hours postoperatively)
  • complication of nerve block(first 24 hours postoperatively)
  • heart rate of the patients(first 24 hours postoperatively)

Study Sites (1)

Loading locations...

Similar Trials